SCHEMBL1737335

SCHEMBL1737335

CCCS(=O)(=O)N1C[C@@H](C(=O)OC)N(c2ccc(F)cc2F)C1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR7 P34969 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
CYP3A4 P08684 2/20 0.35
ATM Q13315 1/20 0.35
USP2 O75604 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HSD17B10 Q99714 1/20 0.35
NPC1 O15118 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
HTT P42858 1/20 0.34
ALDH1A1 P00352 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1735803 0.89 HTR7 (0.36) HTR7SMN1; SMN2LMNATP53L3MBTL1
SCHEMBL1737333 0.83 ACACB (0.38) HTR7SMN1; SMN2LMNATP53CYP3A4
SCHEMBL1736744 0.79 GAA (0.40) CYP3A4CYP1A2CYP2C9CYP2C19HSD17B10
SCHEMBL1735801 0.71 ACACB (0.36) HTR7SMN1; SMN2LMNATP53L3MBTL1
SCHEMBL1736512 0.67 GAA (0.40) SMN1; SMN2LMNACYP3A4CYP1A2CYP2C9
SCHEMBL21660809 0.67 GAA (0.42) TP53L3MBTL1CYP3A4NPC1GAA
SCHEMBL4214246 0.65 SLC6A9 (0.48) HTR7SMN1; SMN2LMNAL3MBTL1CYP3A4
SCHEMBL1734697 0.64 MMP2 (0.41) SMN1; SMN2LMNACYP3A4CYP1A2HTT
SCHEMBL14833279 0.63 ATM (0.37) SMN1; SMN2LMNATP53L3MBTL1ATM
SCHEMBL1734637 0.62 MMP2 (0.49) CYP3A4CYP2C9CYP2C19ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 WO disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 US disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 HTR7 2702/4885SMN1; SMN2 3502/4885LMNA 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.